NANOBIOTIX Provides Third Quarter 2023 Operational and Financial Update
Retrieved on:
Monday, November 13, 2023
Webcast, Lung, Pancreatic cancer, Johnson & Johnson, University, Conference call, Clinical trial, ESMO, Phase 1, NANO, PFS, Patient, Dilute budgerigar mutation, CET, Monroe Dunaway Anderson, BofA Securities, DCR, Nanobiotix, NBTXR3, Conference, EIB, Bloomberg, RT, Cancer, European Investment Bank, Survival, Janssen, Oncology, MD Anderson Cancer Center, OS, AACR, Pharmaceutical industry, Security (finance), Sales, Medical imaging, Palladium, Bank, Euronext
PARIS and CAMBRIDGE, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today provided an update on operational progress and reported financial results for the third quarter of 2023.
Key Points:
- “Our robust NBTXR3 clinical program continues to demonstrate potentially transformative efficacy and well-tolerated safety across indications and patient types, including elderly and vulnerable populations.
- Nanobiotix will host a conference call and live audio webcast on Tuesday, November 14, 2023, at 8:00 am ET / 2:00 pm CET, prior to the open of the U.S. market.
- During the call, Laurent Levy, chief executive officer, and Bart van Rhijn, chief financial officer, will briefly review the Company’s operational progress, provide an update on business activities for the third quarter of 2023, and review the latest data presented at the 2023 Annual Congress of the European Society for Medical Oncology (ESMO), before taking questions from participants.
- A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the Company’s website.